{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:40:05Z","timestamp":1716396005664},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s12265-013-9536-2","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T21:16:40Z","timestamp":1389043000000},"page":"64-71","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation"],"prefix":"10.1007","volume":"7","author":[{"given":"N.","family":"Bennaghmouch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sprenkeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Qaderdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"9536_CR1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Sch\u00f6mig","year":"1996","unstructured":"Sch\u00f6mig, A., Neumann, F. J., Kastrati, A., et al. (1996). A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. The New England Journal of Medicine, 334, 1084\u20131089.","journal-title":"The New England Journal of Medicine"},{"key":"9536_CR2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"CL Grines","year":"2007","unstructured":"Grines, C. L., Bonow, R. O., Casey, D. E., Jr., et al. (2007). Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 115, 813\u2013818.","journal-title":"Circulation"},{"issue":"23","key":"9536_CR3","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm, C. W., Bassand, J. P., Agewall, S., et al. (2011). ESC committee for practice guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32(23), 2999\u20133054.","journal-title":"European Heart Journal"},{"issue":"2\u20133","key":"9536_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0049-3848(03)00143-9","volume":"109","author":"A Schlitt","year":"2003","unstructured":"Schlitt, A., von Bardeleben, R. S., Ehrlich, A., et al. (2003). Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thrombosis Research, 109(2\u20133), 131\u2013135.","journal-title":"Thrombosis Research"},{"key":"9536_CR5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","volume":"28","author":"PP Karjalainen","year":"2007","unstructured":"Karjalainen, P. P., Porela, P., Ylitalo, A., et al. (2007). Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. European Heart Journal, 28, 726\u2013732.","journal-title":"European Heart Journal"},{"key":"9536_CR6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"RG Hart","year":"1999","unstructured":"Hart, R. G., Benavente, O., McBride, R., et al. (1999). Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of Internal Medicine, 131, 492\u2013501.","journal-title":"Annals of Internal Medicine"},{"key":"9536_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","volume":"103","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Huber, K., Andreotti, F., et al. (2010). European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting. Thrombosis and Haemostasis, 103, 13\u201328.","journal-title":"Thrombosis and Haemostasis"},{"key":"9536_CR8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly, S., Pogue, J., Hart, R., et al. (2006). ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet, 367, 1903\u20131912.","journal-title":"Lancet"},{"issue":"19","key":"9536_CR9","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","volume":"288","author":"C Walraven Van","year":"2002","unstructured":"Van Walraven, C., Hart, R. G., Singer, D. E., et al. (2002). Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA, 288(19), 2441\u20132448.","journal-title":"JAMA"},{"key":"9536_CR10","volume":"3","author":"MI Aguilar","year":"2007","unstructured":"Aguilar, M. I., Hart, R., & Pearce, L. A. (2007). Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, 3, CD006186.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"9536_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/07853890802089786","volume":"40","author":"A Rubboli","year":"2008","unstructured":"Rubboli, A., Halperin, J. L., Airaksinen, K. E., et al. (2008). Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Annals of Medicine, 40, 428\u2013436.","journal-title":"Annals of Medicine"},{"key":"9536_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","volume":"103","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Huber, K., Andreotti, F., et al. (2010). European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting. Thrombosis and Haemostasis, 103, 13\u201328.","journal-title":"Thrombosis and Haemostasis"},{"key":"9536_CR13","first-page":"1360","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm, A. J., Kirchhof, P., & Lip, G. Y. (2010). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 31, 1360\u20131420.","journal-title":"European Heart Journal"},{"key":"9536_CR14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1160\/TH11-04-0262","volume":"106","author":"DP Faxon","year":"2011","unstructured":"Faxon, D. P., Eikelboom, J. W., Berger, P. B., et al. (2011). Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thrombosis and Haemostasis, 106, 572\u2013584.","journal-title":"Thrombosis and Haemostasis"},{"key":"9536_CR15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","volume":"126","author":"M Lamberts","year":"2012","unstructured":"Lamberts, M., Olesen, J. B., Ruwald, M. H., et al. (2012). Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation, 126, 1185\u20131193.","journal-title":"Circulation"},{"issue":"378","key":"9536_CR16","first-page":"013","volume":"15","author":"A Krasner","year":"2013","unstructured":"Krasner, A., & Halperin, J. L. (2013). Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review. Current Cardiology Reports, 15(378), 013\u20130378-y.","journal-title":"Current Cardiology Reports"},{"key":"9536_CR17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2010.11.019","volume":"148","author":"F Gao","year":"2011","unstructured":"Gao, F., Zhou, Y. J., Wang, Z. J., et al. (2011). Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. International Journal of Cardiology, 148, 96\u2013101.","journal-title":"International Journal of Cardiology"},{"key":"9536_CR18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","volume":"139","author":"HJ Zhao","year":"2011","unstructured":"Zhao, H. J., Zheng, Z. T., Wang, Z. H., et al. (2011). \u201cTriple therapy\u201d rather than \u201ctriple threat\u201d: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest, 139, 260\u2013270.","journal-title":"Chest"},{"key":"9536_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1753944710391925","volume":"5","author":"PP Singh","year":"2011","unstructured":"Singh, P. P., Singh, M., Bedi, U., et al. (2011). Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. Therapeutic Advances in Cardiovascular Disease, 5, 23\u201331.","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"9536_CR20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cjca.2012.06.012","volume":"29","author":"JG Andrade","year":"2013","unstructured":"Andrade, J. G., Deyell, M. W., Khoo, C., et al. (2013). Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis. The Canadian Journal of Cardiology, 29, 204\u2013212.","journal-title":"The Canadian Journal of Cardiology"},{"key":"9536_CR21","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3760\/cma.j.issn.0366-6999.20130359","volume":"126","author":"KJ Saheb","year":"2013","unstructured":"Saheb, K. J., Deng, B. Q., Hu, Q. S., et al. (2013). Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis. Chinese Medical Journal, 126, 2536\u20132542.","journal-title":"Chinese Medical Journal"},{"issue":"16","key":"9536_CR22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen, M. L., S\u00f8rensen, R., Clausen, M. T., et al. (2010). Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Archives of Internal Medicine, 170(16), 1433\u20131441.","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"9536_CR23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","volume":"8","author":"JG Smith","year":"2012","unstructured":"Smith, J. G., Wieloch, M., Koul, S., et al. (2012). Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention, 8(6), 672\u2013678.","journal-title":"EuroIntervention"},{"issue":"10","key":"9536_CR24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","volume":"126","author":"M Lamberts","year":"2012","unstructured":"Lamberts, M., Olesen, J. B., Ruwald, M. H., et al. (2012). Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation, 126(10), 1185\u20131193.","journal-title":"Circulation"},{"issue":"11","key":"9536_CR25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L., Becker, R. C., Budaj, A., et al. (2009). PLATO Investigators, Freij A, Thors\u00e9n M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361(11), 1045\u201357.","journal-title":"N Engl J Med"},{"issue":"9665","key":"9536_CR26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot, G., Wiviott, S. D., Braunwald, E., et al. (2009). TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 373(9665), 723\u2013731.","journal-title":"Lancet"},{"issue":"20","key":"9536_CR27","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D., Braunwald, E., McCabe, C. H., et al. (2007). TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357(20), 2001\u20132015.","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"9536_CR28","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff, N., Martischnig, A., Wealer, J., et al. (2013). Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. Journal of the American College of Cardiology, 61(20), 2060\u20132066.","journal-title":"Journal of the American College of Cardiology"},{"key":"9536_CR29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin, L., Wilcox, R. G., Weaver, W. D., et al. (2003). Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet, 362, 789\u2013797.","journal-title":"Lancet"},{"key":"9536_CR30","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander, J. H., Becker, R. C., Bhatt, D. L., et al. (2009). Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation, 119, 2877\u20132885.","journal-title":"Circulation"},{"key":"9536_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega, J. L., Braunwald, E., Mohanavelu, S., et al. (2009). Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, 374, 29\u201338.","journal-title":"Lancet"},{"key":"9536_CR32","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren, J., Budaj, A., Granger, C. B., et al. (2011). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal, 32, 2781\u20132789.","journal-title":"European Heart Journal"},{"key":"9536_CR33","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","volume":"32","author":"PG Steg","year":"2011","unstructured":"Steg, P. G., Mehta, S. R., Jukema, J. W., et al. (2011). RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal, 32, 2541\u20132554.","journal-title":"European Heart Journal"},{"key":"9536_CR34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander, J. H., Lopes, R. D., Set, J., et al. (2011). Apixaban with antiplatelet therapy after acute coronary syndrome. The New England Journal of Medicine, 365, 699\u2013708.","journal-title":"The New England Journal of Medicine"},{"key":"9536_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega, J. L., Braunwald, E., Wiviott, S. D., et al. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine, 366, 9\u201319.","journal-title":"The New England Journal of Medicine"},{"issue":"20","key":"9536_CR36","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archinternmed.2012.4026","volume":"172","author":"A Komocsi","year":"2012","unstructured":"Komocsi, A., Vorobcsuk, A., Kehl, D., et al. (2012). Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Archives of Internal Medicine, 172(20), 1537\u20131545.","journal-title":"Archives of Internal Medicine"},{"issue":"22","key":"9536_CR37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","volume":"34","author":"J Oldgren","year":"2013","unstructured":"Oldgren, J., Wallentin, L., Alexander, J. H., et al. (2013). New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. European Heart Journal, 34(22), 1670\u20131680.","journal-title":"European Heart Journal"},{"issue":"9872","key":"9536_CR38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde, W. J., Oirbans, T., Verheugt, F. W., et al. (2013). WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 381(9872), 1107\u20131115.","journal-title":"Lancet"},{"key":"9536_CR39","unstructured":"Van Es, R. F., Jonker, J. J. C., Verheugt, F.W. A., for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) research group., et al. (2002). Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet, 360(9327), 109\u2013113."},{"key":"9536_CR40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen, M., Abdelnoor, M., Smith, P., et al. (2002). Warfarin, aspirin, or both after myocardial infarction. The New England Journal of Medicine, 347, 969\u2013974.","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"9536_CR41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","volume":"62","author":"M Lamberts","year":"2013","unstructured":"Lamberts, M., Gislason, G. H., Olesen, J. B., et al. (2013). Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. Journal of the American College of Cardiology, 62(11), 981\u2013989.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"9536_CR42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00392-013-0592-z","volume":"102","author":"Y Seivani","year":"2013","unstructured":"Seivani, Y., Abdel-Wahab, M., Geist, V., Richardt, et al. (2013). Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clinical Research in Cardiology, 102(11), 799\u2013806.","journal-title":"Clinical Research in Cardiology"},{"issue":"2","key":"9536_CR43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcin.2011.10.013","volume":"5","author":"EJ Armstrong","year":"2012","unstructured":"Armstrong, E. J., Feldman, D. N., Wang, T. Y., et al. (2012). Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC: Cardiovascular Interventions, 5(2), 131\u2013140.","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"25","key":"9536_CR44","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","volume":"119","author":"AJMDSM Kirtane","year":"2009","unstructured":"Kirtane, A. J. M. D. S. M., Gupta, A. M. D., Iyengar, S. M. D., et al. (2009). Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation, 119(25), 3198\u20133206.","journal-title":"Circulation"},{"issue":"9562","key":"9536_CR45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","volume":"369","author":"J Daemen","year":"2007","unstructured":"Daemen, J., Wenaweser, P., Tsuchida, K., et al. (2007). Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 369(9562), 667\u2013678.","journal-title":"Lancet"},{"issue":"9281","key":"9536_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta, S. R., Yusuf, S., Peters, R. J., et al. (2001). Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 358(9281), 527\u2013533.","journal-title":"Lancet"},{"issue":"19","key":"9536_CR47","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl, S. R., Berger, P. B., Mann, J. T., III, et al. (2002). CREDO investigators: Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288(19), 2411\u20132420.","journal-title":"JAMA"},{"issue":"17","key":"9536_CR48","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"I Iakovou","year":"2005","unstructured":"Iakovou, I., Schmidt, T., Bonizzoni, E., et al. (2005). Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293(17), 2126\u20132130.","journal-title":"JAMA"},{"issue":"2","key":"9536_CR49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","volume":"297","author":"EL Eisenstein","year":"2007","unstructured":"Eisenstein, E. L., Anstrom, K. J., Kong, D. F., et al. (2007). Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 297(2), 159\u2013168.","journal-title":"JAMA"},{"issue":"12","key":"9536_CR50","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2006.10.026","volume":"48","author":"M Pfisterer","year":"2006","unstructured":"Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., et al. (2006). BASKET-LATE investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. Journal of the American College of Cardiology, 48(12), 2584\u20132591.","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"9536_CR51","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","volume":"33","author":"S Cassese","year":"2012","unstructured":"Cassese, S., Byrne, R. A., Tada, T., King, L. A., & Kastrati, A. (2012). Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. European Heart Journal, 33(24), 3078\u20133087.","journal-title":"European Heart Journal"},{"key":"9536_CR52","doi-asserted-by":"crossref","unstructured":"Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA Oct 2013. [Epub ahead of print].","DOI":"10.1001\/jama.2013.282183"},{"key":"9536_CR53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon, H. C., Hahn, J. Y., Park, K. W., et al. (2012). Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 125, 505.","journal-title":"Circulation"},{"key":"9536_CR54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim, B. K., Hong, M. K., Shin, D. H., et al. (2012). A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-eluting Stent Implantation). Journal of the American College of Cardiology, 60, 1340.","journal-title":"Journal of the American College of Cardiology"},{"key":"9536_CR55","unstructured":"ClinicalTrials.gov. Anticoagulation in stent intervention (MUSICA-2). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01141153 [Last access at 4-12-2013]."},{"key":"9536_CR56","unstructured":"ClinicalTrials.gov. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin k antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01830543 . [Last access at 4-12-2013]."},{"key":"9536_CR57","unstructured":"ClinicalTrials.gov. Triple therapy in patients on oral anticoagulation after drug eluting stent implantation (ISAR-TRIPLE). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00776633 . [Last access at 4-12-2013]."},{"key":"9536_CR58","unstructured":"ClinicalTrials.gov. Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00661206 . [Last access at 4-12-2013]."},{"key":"9536_CR59","unstructured":"ClinicalTrials.gov. The dual antiplatelet therapy study (DAPT study). Available at: http:\/\/clinicaltrials.gov\/show\/NCT00977938 . [Last access at 4-12-2013]."}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-013-9536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-013-9536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-013-9536-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:14:43Z","timestamp":1716394483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-013-9536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["9536"],"URL":"https:\/\/doi.org\/10.1007\/s12265-013-9536-2","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]}}}